Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03488550 · ClinicalTrials.gov registry record · Phase 1
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
A Phase 1 study, sponsored by Annexon.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03488550: Completed Phase 1 study, sponsored by Annexon.
NCT03488550 is a Phase 1 study that has completed, run by Annexon. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03488550, a Phase 1 study, has completed, sponsored by Annexon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
Interventions
- BIOLOGICAL ANX007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-03-23 |
| Est. Completion | 2018-08-03 |
| Phase | Phase 1 |
What the finished NCT03488550 record still lists
NCT03488550 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which ANX007 is the first listed.
NCT03488550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03488550 about?
NCT03488550 is a clinical study titled "Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma". This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
What is the current status of trial NCT03488550?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-03-23. Estimated completion is 2018-08-03.
What interventions are being tested in trial NCT03488550?
The interventions under investigation include: ANX007 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03488550?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03488550's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI